PARC: A Phase I / II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in RElapsed/refractory Cancers of childhood

Project Details

Short titlePARC: A Phase I / II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in RElapsed/refractory Cancers of childhood
StatusActive
Effective start/end date1/12/1731/03/24

Funding

  • INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER (ITCC)
  • BIO-CANCER TREATMENT INTERNATIONAL LTD
  • Cancer Research Uk

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.